Developing Drug Products in an Aging Society

From Concept to Prescribing

  • Sven Stegemann

Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 26)

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Introduction

  3. The Patient(s)

    1. Front Matter
      Pages 59-59
    2. Jean-Pierre Baeyens
      Pages 61-66
    3. Paul A. F. Jansen
      Pages 67-86
    4. Jacob Blumenthal, Steven R. Gambert
      Pages 87-101
  4. Clinical Development of Drug Products for Older Adults

    1. Front Matter
      Pages 115-115
    2. Florian von Raison and Laurence Hugonot-Diener on behalf of the Geriatric Medicine Working Party (GMWP), European Forum of Good Clinical Practice (EFGCP)
      Pages 117-128
    3. Jatinder Kaur Mukker, Ravi Shankar Prasad Singh, Hartmut Derendorf
      Pages 139-151
  5. Product Development for Older Adults

  6. Drug Therapy in Older Adults

    1. Front Matter
      Pages 517-517
    2. Sunny A. Linnebur
      Pages 519-547
    3. Jennifer G. Naples, Emily R. Hajjar
      Pages 549-561
    4. Andreas H. Leischker
      Pages 563-576
    5. Emily P. Peron, Kelechi C. Ogbonna
      Pages 577-588
    6. Jan F. Schlender, Adam G. Golden, Tanay S. Samant, Chakradhar V. Lagishetty, Stephan Schmidt
      Pages 589-611
  7. Management of Drug Therapy in Older Adults

    1. Front Matter
      Pages 627-627
    2. Gabriel Ariza, Marta Martínez-Reig, Pedro Abizanda
      Pages 629-657
    3. Hubert Ebner, Günter Schreier
      Pages 659-674
    4. Mirko Petrovic, Annemie Somers, Graziano Onder
      Pages 683-697
  8. Regulatory Guidance on Geriatric Medicines

    1. Front Matter
      Pages 699-699
    2. S. W. Johnny Lau, Raman K. Baweja
      Pages 719-734
  9. Concluding Remarks

    1. Front Matter
      Pages 735-735
    2. Amanda Lavan, Paul Gallagher, Denis O’Mahony
      Pages 737-757
  10. Back Matter
    Pages 769-771

About this book


This book aims to address the major aspects of future drug product development and therapy for older adults, giving practical guidance for the rational product and clinical development and prescribing of drug products to this ever growing segment of the population. With authors coming from key “aging” markets such as Europe, the USA, China and Japan, the book will provide valuable information for students, scientists, regulators, practitioners, and other healthcare professionals from academia, industry and regulatory bodies.


adherence aging drug development regulations geriatric drug dosage multimorbidity polypills healthcare

Editors and affiliations

  • Sven Stegemann
    • 1
  1. 1.Graz University of TechnologyGrazAustria

Bibliographic information

Industry Sectors
Health & Hospitals
Consumer Packaged Goods